Recent Senate Bill Aims to Unlock Psychedelic Therapies for Veterans
A new bipartisan push in the Senate seeks to expand research and access to psychedelic-assisted therapies for veterans struggling with mental health conditions. Senator Tim Sheehy (R-MT) is sponsoring the “Veterans Health Administration Novel Therapeutics Preparedness Act,” which would establish an Office of Novel Therapeutics within the Department of Veterans Affairs (VA) to streamline studies into emerging treatments.
Addressing a Critical Need
The legislation recognizes the disproportionately high rates of PTSD, depression, and substance use disorders among veterans. It highlights that existing treatments aren’t always effective, creating a need to explore innovative options. The bill specifically mentions psychedelics under evaluation by the Food and Drug Administration (FDA), acknowledging their potential to significantly alter the treatment landscape.
What the Bill Proposes
The core of the bill centers around establishing a dedicated Office of Novel Therapeutics within the VA. This office would be responsible for facilitating research initiatives focused on substances currently under FDA review. At least one “Center of Excellence” would be established in each VA regional district to develop a national model for implementing these therapies. A Veteran Advisory Committee, comprised of veterans, experts, and health professionals, will provide guidance on access and safety protocols.
Collaboration with Federal Agencies
The bill emphasizes the importance of interagency collaboration. The VA would be required to coordinate with the Department of Health and Human Services (HHS), FDA, Centers for Medicare & Medicaid Services (CMS), the Department of Defense (DOD), and the Drug Enforcement Administration (DEA). This collaboration aims to address regulatory hurdles, potential rescheduling of psychedelic substances, and ensuring healthcare coverage for access to these treatments.
Building on Existing Momentum
This bill isn’t the first attempt to address psychedelic therapies for veterans. Similar legislation, sponsored by Senators Ruben Gallego (D-AZ) and David McCormick (R-PA), proposes $30 million in annual funding for psychedelic-focused “centers of excellence” within the VA. A companion bill in the House, sponsored by Representatives Lou Correa (D-CA) and Jack Bergman (R-MI), has likewise been introduced, though it has yet to advance.
Support from the Trump Administration
The effort has garnered support from within the Trump administration. VA Secretary Doug Collins and HHS Secretary Robert F. Kennedy, Jr. Have both expressed openness to psychedelic policy reform. Kennedy has publicly stated the administration is “very anxious” to create a pathway for these novel therapies, aiming for access within 12 months.
Veterans Groups Advocate for Change
Veterans groups are also actively advocating for expanded access to psychedelics and marijuana. Organizations like the Wounded Warrior Project (WWP) and Veterans of Foreign Wars (VFW) have specifically endorsed the Innovative Therapies Centers of Excellence Act, recognizing its potential to address the veteran suicide crisis.
Recent VA Actions and Research
In December 2024, the VA announced funding for a study on MDMA-assisted therapy for PTSD and alcohol use disorder, marking the first time the agency has funded psychedelic research since the 1960s. However, the VA faced criticism in 2024 for rejecting a grant application from an organization assisting veterans in accessing psychedelic therapy programs abroad.
What Psychedelics are Being Considered?
While the bills often use broad terms like “novel therapies,” specific substances mentioned in related discussions include MDMA, psilocybin, ibogaine, ketamine, and 5-MeO-DMT. These compounds are being investigated for their potential to treat a range of conditions, including PTSD, traumatic brain injury, depression, substance use disorders, and chronic pain.
FAQ
Q: What is the purpose of the Innovative Therapies Centers of Excellence Act?
A: The bill aims to increase federally funded research on innovative therapies, including psychedelics, to treat veterans experiencing PTSD, substance use disorder, and depression.
Q: Which psychedelic substances are being considered for research?
A: MDMA, psilocybin, ibogaine, ketamine, and 5-MeO-DMT are among the compounds under study.
Q: What role will the Veteran Advisory Committee play?
A: The committee will advise on matters such as access barriers and safety protocols related to these therapies.
Q: Is the Trump administration supportive of psychedelic research?
A: Yes, both VA Secretary Doug Collins and HHS Secretary Robert F. Kennedy, Jr. Have expressed support for exploring psychedelic therapies.
Q: What is the status of the companion bill in the House?
A: A companion bill has been introduced in the House but has not yet advanced.
Did you realize? The VA hasn’t funded psychedelic research since the 1960s, making the recent funding for MDMA-assisted therapy a significant shift.
Pro Tip: Stay informed about the latest developments in psychedelic research by following reputable news sources and organizations dedicated to the field.
Want to learn more about innovative therapies for veterans? Explore our other articles on mental health and veteran affairs.
